FDA inspection
The Johns Hopkins Hospital HATS Service: FDA inspection ending Jan 22, 2004
FDA inspection 316671 · Voluntary Action Indicated (VAI) · Baltimore, MD
Key facts
| Inspection ID | 316671 |
|---|---|
| Firm | The Johns Hopkins Hospital HATS Service |
| FEI number | 1177527 |
| Address | 550 N Broadway Ste 810 |
| City | Baltimore |
| State | MD |
| ZIP | 21205-2000 |
| Fiscal year | 2004 |
| Inspection end date | Jan 22, 2004 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation |
| Product type | Biologics, Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data